Abstract
We have previously shown that 3 week oral VOSO4 treatment of streptozotocin (STZ, 60 mg/kg)-induced diabetic rats was able to correct diabetes for 13 weeks after treatment withdrawal. In the present study, we investigated whether a short-term (8 days) i.p. VOSO4 treatment was similarly able to reverse the diabetic state. Insulin secretory capacities were assessed at distance of treatment using the isolated pancreas preparation. Seven treatment-groups were performed: high dose VOSO4-treated diabetics (HVD, 1.3 mM/kg/8 days), food-restricted diabetics (FRD, food adjusted to HVD levels), low dose VOSO4-treated diabetes (LVD, 0.06 mM/kg/day), insulin-treated diabetics (ID, dose adjusted to normalize glycaemia) and VOSO4 (0.06 mM/kg/day) + insulin (dose adjusted to normalize glycaemia in the presence of vanadium)-treated diabetics (IVD), in addition to the corresponding untreated non-diabetic controls (C) and diabetics (D). Our results indicate that long-term correction of diabetes (a) can be obtained after an 8 day treatment using i.p. VOSO4 in diabetic animals retaining some degree of pancreatic function, (b) is not obtained with insulin treatment or food restriction although the association of VOSO4 and insulin was found beneficial, (c) can be prolonged in some individuals for at least 4 months, i.e. in conditions such that tissue vanadium concentrations had returned to values close to pre-treatment levels, (d) is associated with improved and in some cases normalized insulin secretion from isolated pancreas. The protective or corrective role of VOSO4 on diabetes-related pancreatic alterations, as well as the potential of the VOSO4-insulin association should be further studied in view of the possible use of vanadium derivatives in the treatment of diabetes.
Similar content being viewed by others
References
Shechter Y, Karlish SJD: Insulin-like stimulation of glucose oxydation in rat adipocytes by vanadyl (IV) ion. Nature 284: 556–558, 1980
Rodriguez-Gil JE, Gomez-Foix AM, Fillat C, Bosch F, Guinovart J-J: Activation by vanadate of glycolysis in hepatocytes from diabetic rats. Diabetes 40: 1355–1359, 1991
Aguis L, Vaartjes WJ: The effects of orthovanadate on fatty acid synthesis in isolated rat hepatocytes. Biochem. J. 202: 791–794, 1982
Castro J, Maquedano A, Olive M: Lipid synthesis in isolated rat hepatocytes: activation by insulin and vanadate and inhibition by ouabain. Biochem Inter 9: 413–420, 1984
Ramanadham S, Mongold JJ, Brownsey R, Cros GH, McNeill JH: Oral vanadyl sulfate in treatment o diabetes mellitus in rats. Am. J. Physiol. 257 (Heart Circ. Physiol. 26): H904-H911 1989
Sakurai H, Tschiya K, Nukatsuka M, Sofue M, Kawada J: Insulin-like effect of vanadyl ion on streptozotocin-induced diabetic rats. J. Endocrinol 126: 451–459, 1990
Heyliger CE, Tahiliani AG, McNeill JH: Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science 227: 1474–1477, 1985
Meyerovitch J, Farfel Z, Sack J, Shechter Y: Oral administration of vanadate normalizes blood glucose levels in streptozotocin-diabetic rats. Characterization and mode of action. J Biol Chem 262: 6658–6662, 1987
Shisheva A, Ikonomov O, Shechter Y: The protein phosphatase inhibitor, pervanadate, is a powerful antidiabetic agent in streptoztocintreated rats. Endocrinology 134: 507–510, 1994
Meyerovitch J, Rothenberg P, Shechter T, Bonner-Weir S, Kahn CR: Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus. J Clin Invest 87: 1286–1294, 1991
Pugazhenthi S, Angel JF, Khandelwal RL: Long-term effects of vanadate treatment on glycogen metabolizing and lipogenic enzymes of liver in genetically diabetic (db/db) mice. Metabolism 40: 941–946, 1991
Battell ML, Yuen VG, McNeill JH: Treatment of BB rats with vanadyl sulfate. Pharmacol Commun 1: 291–301, 1992
Ramanadham S, Cros GH, Mongold JJ, Serrano JJ, McNeill JH: Enhancedin vivo sensitivity of vanadyl-treated diabetic rats to insulin. Can J Physiol Pharmacol 68: 486–491, 1990
Ramanadham S, Brownsey RW, Cros GH, Mongold J-J, McNeill JH: Sustained prevention of myocardial and metabolic abnormalities in diabetic rats following withdrawal from oral vanadyl treatment. Metabolism 38: 1022–1028, 1989
Dai S, Thompson KH, McNeill JH: One-year treatment of Streptozotocin-induced diabetic rats with vanadyl sulfate. Pharmacology and Toxicology 74: 101–109, 1994
Cam MC, Faun J, McNeill JH: Concentration-dependent glucose lowering effects of oral vanadyl are maintained following treatment withdrawal in streptozotocin-diabetic rats. Metab Clin Exp 44: 332–339, 1995
Pederson RA, Ramanadham S, Buchan AMJ, McNeill JH: Long-term effects of vanadyl treatment on streptozotocin-induced diabetes in rats. Diabetes 38: 1390–1395, 1989
Loubatieres A, Mariani MM, Ribes G, De Malbosc H, Chapal J: Etude experimentale d'un noueau sulfamide hypoglycémiant particulierèment actif, le HB 419 ou glibenclamide. I. Action betacytotrope et insulinosécrétrice. Diabetologia 5: 1–10, 1969
Herbert V, Lau KS, Gottlieb CW, Bleicher SJ: Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 25: 1375–1384, 1965
Mongold JJ, Cros GH, Vian L, Tep A, Ramanadham S, Siou G, Diaz J, McNeill JH, Serrano JJ: Toxicological aspects of vanadyl sulfate on diabetic rats: effects on vanadium levels and pancreatic B-cell morphology. Pharmacol Toxicol: 67: 192–198, 1990
Unger RH, Grundy: Hyperglycemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implication for the management of diabetes. Diabetologia 28: 119–121, 1985
Guastamacchia E, Ciampolillo A, Lattanzi V, Lollino G, Rosco M, Lucivero G, Dell'Osso A, Giorgino R, Naredelli GM: In search of predictive markers of remission from insulin dependence in type i diabetes: a preliminary report. Diab Res Clin Pract 16: 145–149, 1992
Buschard K: The functional state of the beta-cells in the pathogenesis of insulin-dependent diabetes mellitus. Autoimmunity 10: 65–69, 1991
Malabu UH, Dryden S, McCarthy DMC, Kilpatrick A, Williams G: Effects of chronic vanadate administration in the STZ-induced diabetic rat. The antihyperglycemic action of vanadate is attributable entirely to its suppression of feeding. Diabetes 43: 9–15, 1994
Parker RDR, Shama RP: Accumulation and depletion of vanadium in selected tissues of rats treated with vanadyl sulfate and sodium orthovanadate. J Environ Pathol Toxicol 2: 235–245, 1978
Al-Bayati M, Raabe OG, Giri SN, Knaak JB: Distribution of vanadate in the rat following subcutaneous an oral routes of administration. J Am Coll Toxicol 10: 233–241, 1991
Fagin JA, Ikejiri K, Levin SR: Insulinotropic effects of vanadate. Diabetes 36: 1448–1452, 1991
Zhang A, Gao Z-Y, Gilon P, Nenquin M, Drews G, Henquin IC: Vanadate stimulation of insulin release in normal mouse islets. J Biol Chem 266: 21649–21656, 1991
Voss C, Herrmann I, Hartmann K, Zuhlke H:In vitro effect of vanadate on content, secretion and biosynthesis of insulin in isolated islets of normal Wistar rats. Exp Clin Endocrinol 99: 159–163, 1992
Cam MC, Pederson RA, Brownsey RW, McNeill JH: Long-term effectiveness of oral vanadyl sulphate in streptozotocin-diabetic rats. Diabetologia 36: 218–224, 1993
Rijksen G, Voller MVW, Van Zoellen EJJ: Orthovanadate both mimics and antagonizes the transforming growth factor z action on normal rat kidney cells. J Cell Physiol 154: 393–401, 1993.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Poucheret, P., Gross, R., Cadène, A. et al. Long-term correction of STZ-diabetic rats after short-term i.p. VOSO4 treatment: Persistence of insulin secreting capacities assessed by isolated pancreas studies. Mol Cell Biochem 153, 197–204 (1995). https://doi.org/10.1007/BF01075938
Issue Date:
DOI: https://doi.org/10.1007/BF01075938